Skip to content

Author

Massimo Filippi

We have 9 of 45 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Anti‐CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis

Highly effective (HE) disease‐modifying therapies (DMTs) reduce relapse‐associated worsening (RAW) and progression independent of relapse activity (PIRA). Natalizumab (NTZ) and anti‐CD20 agents show similar efficacy on relapse suppression, but long‐term comparative data on PIRA are limited. We aimed to compare PIRA acc...

L. Palazzo, F. Clarelli, Michele Surano et al. · 0 citations
Open access Oct 2026

Advanced age at onset is associated with distinct functional brain reorganization in multiple sclerosis

Abstract Functional network reorganization supports compensatory mechanisms in multiple sclerosis, but ageing and later disease onset may alter this balance. Late-onset multiple sclerosis (age at onset ≥50 years) represents a relevant subgroup to examine how disease onset in older age is associated with functional conn...

Nicolò Tedone, P. Valsasina, A. Meani et al. · 0 citations
Open access Oct 2026

Functional and Structural Imaging Features of Cognitive Profiles in Multiple Sclerosis

Background and Objectives Cognitive impairment affects 40%–70% of patients with multiple sclerosis (MS). Although recent hypothesis-driven and data-driven efforts have identified cognitive phenotypes, functional substrates underlying impairment in such phenotypes are still not clear. Our objective was to identify disti...

Kshiteeja Jain, P. Valsasina, Damiano Mistri et al. · 0 citations
Review Open access Sep 2026

Developmental brain programmes and biomarker activation in Alzheimer’s disease

Abstract Recent studies show that serum glial fibrillary acidic protein (GFAP) is highest in healthy infancy and early childhood and then declines steadily with age, while plasma tau protein phosphorylated at position 217 is strikingly elevated in healthy newborns and can exceed values observed in Alzheimer’s disease (...

L. Pini, M. Margoni, Massimo Filippi et al. · 0 citations
Open access Oct 2026

Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis

Key Points Question What is the long-term safety and efficacy profile of ocrelizumab in patients with relapsing multiple sclerosis (RMS)? Findings In the OPERA I/II randomized clinical trials including 1656 patients with RMS, treatment with ocrelizumab for up to 10 years led to near-complete and sustained suppression o...

Stephen L. Hauser, Amit Bar-Or, G. Giovannoni et al. · 0 citations
Sep 2026

Imaging subtypes reveal distinct biological substrates and disability profiles in multiple sclerosis.

Multimodal MRI analysed with SuStaIn identified reproducible subtypes of multiple sclerosis with clinically meaningful differences in phenotype, age at onset, disability, and relapse-independent progression, while cognitive impairment was related to advancing SuStaIn stage within each subtype.

P. Preziosa, L. Storelli, F. Clarelli et al. · 0 citations
Review Sep 2026

Pediatric multiple sclerosis: a diagnostic overview and the importance of early identification

This review summarizes the diagnostic work-up of children with a first acquired demyelinating syndrome, differential diagnosis, the role of MRI, cerebrospinal fluid (CSF) markers, antibody testing, serum neurofilament light chain, optical pathway assessment and the 2024 McDonald criteria.

M. Margoni, Massimo Filippi, M. Rocca · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.